World Journal of Endocrine Surgery

Register      Login

VOLUME 16 , ISSUE 2 ( May-August, 2024 ) > List of Articles

ORIGINAL RESEARCH

Utility of Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio as an Adjunct in Predicting Malignancy in Thyroid Nodules

V Sasi Mouli, M Shreyamsa, Kul R Singh, Chanchal Rana, Pooja Ramakant, Anand Mishra

Keywords : Fine needle aspiration cytology, Histopathology, Neutrophil:lymphocyte ratio, Platelet:lymphocyte ratio

Citation Information : Mouli VS, Shreyamsa M, Singh KR, Rana C, Ramakant P, Mishra A. Utility of Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio as an Adjunct in Predicting Malignancy in Thyroid Nodules. World J Endoc Surg 2024; 16 (2):27-31.

DOI: 10.5005/jp-journals-10002-1475

License: CC BY-NC 4.0

Published Online: 06-03-2025

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Background: Preoperative neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) have been associated prognostically in a few cancers. However, the role of these parameters as an adjunct with fine needle aspiration cytology (FNAC) in thyroid nodules is not determined. Objective: To evaluate if these parameters can be used as an adjunct in determining malignancy in thyroid nodules. Materials and methods: A retrospective study of 309 patients from July 2016 to July 2018 undergoing surgery for thyroid nodule was included. Their automated counts with NLR and PLR values were calculated. Receiver operator characteristic (ROC) curve was constructed for NLR and PLR to calculate cutoff, which was used to compare FNAC with histopathology in Bethesda category III and category IV between benign and malignant groups. Results: A total of 309 were included, with a mean age of 38.53 years (range: 10–80 years). Female: male was 261 (84.5%): 48 (15.5%). Benign thyroid nodules (n = 247, 79.9%), of which lymphocytic thyroiditis were 39, and malignancy (n = 62, 20.1%). Median NLR was 2.03, and median PLR was 82.74, which were taken as cutoff; there was a statistically significant difference between benign and malignant nodules (p < 0.001) for both. Similarly, at these cutoff values, Bethesda category III did not show any significant difference between benign and malignancy (p = 0.24), whereas Bethesda category II and IV had statistical significance between benign and malignancy for NLR (p < 0.001 and 0.04, respectively) but not for PLR (p = 1). Conclusion: NLR can be used as an adjunct with FNAC in suspecting malignancy in thyroid nodules.


PDF Share
  1. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:1–133. DOI: 10.1089/thy.2015.0020
  2. Pinchera A, Aghini-Lombardi F, Antonangeli L, et al. Multinodular goiter. Epidemiology and prevention. Ann Ital Chir 1996;67:317–325.
  3. Kocer D, Karakukcu C, Karaman H, et al. May the neutrophil/lymphocyte ratio be a predictor in the differentiation of different thyroid disorders. Asian Pac J Cancer Prev 2015;16:3875–3879. DOI: 10.7314/apjcp.2015.16.9.3875
  4. Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol 2009;132:658–665. DOI: 10.1309/AJCPPHLWMI3JV4LA
  5. Alam T, Khattak YJ, Beg M, et al. Diagnostic accuracy of ultrasonography in differentiating benign and malignant thyroid nodules using fine needle aspiration cytology as the reference standard. Asian Pac J Cancer Prev 2014;15:10039–10043. DOI: 10.7314/apjcp.2014.15.22.10039
  6. Manatakis DK, Tseleni-Balafouta S, Balalis D, et al. Association of baseline neutrophil-to-lymphocyte ratio with clinicopathological characteristics of papillary thyroid carcinoma. Int J Endocrinol 2017;2017:8471235. DOI: 10.1155/2017/8471235
  7. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008;454:436–444. DOI: 10.1038/nature07205
  8. Kim JY, Park T, Jeong SH, et al. Prognostic importance of baseline neutrophil to lymphocyte ratio in patients with advanced papillary thyroid carcinomas. Endocrine 2014;46:526–531. DOI: 10.1007/s12020-013-0089-6
  9. Ozmen S, Timur O, Calik I, et al. Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) may be superior to C-reactive protein (CRP) for predicting the occurrence of differentiated thyroid cancer. Endocr Regul 2017;51:131–136. DOI: 10.1515/enr-2017-0013
  10. Moore MM, Chua W, Charles KA, et al. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther 2010;87:504–508. DOI: 10.1038/clpt.2009.254
  11. Dailey ME, lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg 1955;70(2):291–297. DOI: 10.1001/archsurg.1955.01270080137023
  12. Ward LS. Immune response in thyroid cancer: widening the boundaries. Scientifica (Cairo) 2014;2014:125450. DOI: 10.1155/2014/125450
  13. Guzel AI, Kokanali MK, Erkilinc S, et al. Predictive role of the neutrophil lymphocyte ratio for invasion with gestational trophoblastic disease. Asian Pac J Cancer Prev 2014;15:4203–4206. DOI: 10.7314/apjcp.2014.15.10.4203
  14. He WZ, Jiang C, Yin CX, et al. Prognostic model built on blood-based biomarkers in patients with metastatic colorectal cancer. Asian Pac J Cancer Prev 2014;15:7327–7331. DOI: 10.7314/apjcp.2014.15.17.7327
  15. Kum RO, Ozcan M, Baklaci D, et al. Elevated neutrophil-to-lymphocyte ratio in squamous cell carcinoma of larynx compared to benign and precancerous laryngeal lesions. Asian Pac J Cancer Prev 2014;15:7351–7355. DOI: 10.7314/apjcp.2014.15.17.7351
  16. Ozyalvacli G, Yesil C, Kargi E, et al. Diagnostic and prognostic importance of the neutrophil lymphocyte ratio in breast cancer. Asian Pac J Cancer Prev 2014;15:10363–10366. DOI: 10.7314/apjcp.2014.15.23.10363
  17. Yildirim MA, Seckin KD, Togrul C, et al. Roles of neutrophil/lymphocyte and platelet/lymphocyte ratios in the early diagnosis of malignant ovarian masses. Asian Pac J Cancer Prev 2014;15:6881. DOI: 10.7314/apjcp.2014.15.16.6881
  18. Vassilatou E, Fisfis M, Morphopoulos G, et al. Papillary thyroid carcinoma producing granulocyte-macrophage colony-stimulating factor is associated with neutrophilia and eosinophilia. Hormones (Athens) 2006;5:303. DOI: 10.14310/horm.2002.11196
  19. Delys L, Detours V, Franc B, et al. Gene expression and the biological phenotype of papillary thyroid carcinomas. Oncogene 2007;26:7894. DOI: 10.1038/sj.onc.1210588
  20. Borrello MG, Alberti L, Fischer A, et al. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci USA 2005;102:14825. DOI: 10.1073/pnas.0503039102
  21. Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014;106:dju124. DOI: 10.1093/jnci/dju124
  22. Seretis C, Gourgiotis S, Gemenetzis G, et al. The significance of neutrophil/lymphocyte ratio as a possible marker of underlying papillary microcarcinomas in thyroidal goiters: a pilot study. Am J Surg 2013;205:691. DOI: 10.1016/j.amjsurg.2012.08.006
  23. Bozec A, Lassalle S, Hofman V, et al. The thyroid gland: a crossroad in inflammation-induced carcinoma? An ongoing debate with new therapeutic potential. Curr Med Chem 2010;17:3449. DOI: 10.2174/092986710792927804
  24. Liu CL, Lee JJ, Liu TP, et al. Blood neutrophil-to-lymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer. J Surg Oncol 2013;107:493. DOI: 10.1002/jso.23270
  25. Liu J, Du J, Fan J, et al. The neutrophil-to-lymphocyte ratio correlates with age in patients with papillary thyroid carcinoma. ORL J Otorhinolaryngol Relat Spec 2015;77:109. DOI: 10.1159/000375534
  26. Lang BH, Ng CP, Au KB, et al. Does preoperative neutrophil lymphocyte ratio predict risk of recurrence and occult central nodal metastasis in papillary thyroid carcinoma. World J Surg 2014;38:2605. DOI: 10.1007/s00268-014-2630-z
  27. Kim SM, Kim EH, Kim BH, et al. Association of the preoperative neutrophil-to-lymphocyte count ratio and platelet-to-lymphocyte count ratio with clinicopathological characteristics in patients with papillary thyroid cancer. Endocrinol Metab (Seoul) 2015;30:494–501. DOI: 10.3803/EnM.2015.30.4.494
  28. Gong W, Yang S, Yang X, et al. Blood preoperative neutrophil-to-lymphocyte ratio is correlated with TNM stage in patients with papillary thyroid cancer. Clinics (Sao Paulo) 2016;71:311. DOI: 10.6061/clinics/2016(06)04
  29. Turkmen K, Erdur FM, Ozcicek F, et al. Platelet-to-lymphocyte ratio better predicts inflammation than neutrophil-to-lymphocyte ratio in end-stage renal disease patients. Hemodial Int 2013;17:391. DOI: 10.1111/hdi.12040
  30. Bayır Ö, Karagöz T, Öcal B, et al. Predictive role of neutrophil-lymphocyte and platelet-lymphocyte ratios in thyroid nodules with cytological diagnosis of “undetermined significance” and “suspicious for malignancy.” ENT Updates 2017;7:28–32. DOI: 10.2399/jmu.2017001003
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.